GlassScriptPhysician profile
Mayada Zegar
NPI 1326756321
$2,394.01
in general payments reported to CMS, 2019-2025
17 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $25.55 · 2024: $1,974 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,227 · Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,227.48 |
| Food and Beverage | $1,166.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $1,607.59 | 2023-2024 | Nalu Neurostimulation System |
| Spinal Simplicity, LLC | $139.75 | 2025 | Ha Minuteman G3-R |
| Abbvie INC. | $101.74 | 2024 | |
| Valinor Pharma, LLC | $97.76 | 2024-2025 | Movantik |
| Ucb, INC. | $66.44 | 2024-2025 | Zilbrysq, Briviact |
| Novartis Pharmaceuticals Corporation | $63.34 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $58.04 | 2024-2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $44.67 | 2024 | |
| Celgene Corporation | $34.02 | 2025 | Zeposia |
| Microtransponder, INC. | $33.26 | 2024 | |
| Neurelis, INC. | $32.14 | 2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $23.72 | 2025 | Hyqvia |
| Janssen Biotech, INC. | $21.15 | 2025 | |
| Emd Serono, INC. | $19.35 | 2024 | |
| Amgen INC. | $17.64 | 2024 | Uplizna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.99 | 2024 | Kisunla, Amyvid |
| Mdd US Operations, LLC | $16.41 | 2024 | Apokyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayada Zegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.